Concourse Financial Group Securities, Inc. Day One Biopharmaceuticals, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share
Q3 2024 Oct 10, 2024	BUY	$12.72 - $16.03 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$12.03 - $17.69 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$13.56 - $17.46 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$9.68 - $15.37 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$11.22 - $14.86 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$11.22 - $14.86 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$11.74 - $14.47 $0 - $0
Q1 2023 May 15, 2023	BUY	$12.75 - $23.41 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$18.77 - $22.0 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$16.44 - $26.57 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$5.72 - $17.9 $0 - $0
Q1 2022 May 09, 2022	BUY	$9.12 - $17.47 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$15.65 - $26.33 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$20.0 - $27.92 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$19.0 - $23.69 $0 - $0

Others Institutions Holding DAWN

# of Institutions

181

Shares Held

84.2M

Call Options Held

148K

Put Options Held

218K

Ra Capital Management, L.P. Boston, MA

7.87M
Shares

$96.1 Million
1.53% of portfolio
Atlas Venture Life Science Advisors, LLC

6.43M
Shares

$78.5 Million
11.05% of portfolio
Vanguard Group Inc Valley Forge, PA

5.89M
Shares

$71.9 Million
0.0% of portfolio
Braidwell LP Stamford, CT

4.87M
Shares

$59.5 Million
1.92% of portfolio
Black Rock Inc. New York, NY

4.53M
Shares

$55.4 Million
0.0% of portfolio

View Full List

About Day One Biopharmaceuticals, Inc.

Ticker DAWN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,461,104
Market Cap $897M
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...

More about DAWN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account